Literature DB >> 12788197

Patient-specific point dose measurement for IMRT monitor unit verification.

Lei Dong1, John Antolak, Mohammad Salehpour, Kenneth Forster, Laura O'Neill, Robin Kendall, Isaac Rosen.   

Abstract

PURPOSE: To review intensity-modulated radiation therapy (IMRT) monitor unit verification in a phantom for 751 clinical cases. METHODS AND MATERIALS: A custom water-filled phantom was used to measure the integral dose with an ion chamber for patient-specific quality assurance. The Corvus IMRT planning system was used for all cases reviewed. The 751 clinical cases were classified into 9 treatment sites: central nervous system (27 cases), gastrointestinal (24 cases), genitourinary (447 cases), gynecologic (18 cases), head and neck (200 cases), hematology (12 cases), pediatric (3 cases), sarcoma (8 cases), and thoracic (12 cases). Between December 1998 and January 2002, 1591 measurements were made for these 751 IMRT quality assurance plans.
RESULTS: The mean difference (MD) in percent between the measurements and the calculations was +0.37% (with the measurement being slightly higher). The standard deviation (SD) was 1.7%, and the range of error was from -4.5% to 9.5%. The MD and SD were +0.49% and 1.4% for MIMiC treatments delivered in 2-cm mode (261 cases) and -0.33% and 2.7% for those delivered in 1-cm mode (36 cases). Most treatments (420) were delivered using the step-and-shoot multileaf collimator with a 6-MV photon beam; the MD and SD were +0.31% and 1.8%, respectively. Among the 9 treatment sites, the prostate IMRT (in genitourinary site) was most consistent with the smallest SD (1.5%). There were 23 cases (3.1% of all cases) in which the measurement difference was greater than 3.5%; of those, 6 cases used the MIMiC in 1-cm mode, and 14 of the cases were from the head-and-neck treatment site.
CONCLUSION: IMRT monitor unit calculations from the Corvus planning system agreed within 3.5% with the point-dose ion chamber measurement in 97% of 751 cases representing 9 different treatment sites. A good consistency was observed across sites.

Entities:  

Mesh:

Year:  2003        PMID: 12788197     DOI: 10.1016/s0360-3016(03)00197-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  27 in total

1.  Technical note: Heterogeneity dose calculation accuracy in IMRT: study of five commercial treatment planning systems using an anthropomorphic thorax phantom.

Authors:  Scott E Davidson; Richard A Popple; Geoffrey S Ibbott; David S Followill
Journal:  Med Phys       Date:  2008-12       Impact factor: 4.071

2.  Examining credentialing criteria and poor performance indicators for IROC Houston's anthropomorphic head and neck phantom.

Authors:  Mallory E Carson; Andrea Molineu; Paige A Taylor; David S Followill; Francesco C Stingo; Stephen F Kry
Journal:  Med Phys       Date:  2016-12       Impact factor: 4.071

3.  Dose prescription point in forward intensity-modulated radiotherapy of breast and head/neck cancers.

Authors:  Farzaneh Allaveisi; Nasrin Amini; Sohrab Sakineh Pour
Journal:  Radiol Phys Technol       Date:  2018-09-08

4.  A calibration method for patient specific IMRT QA using a single therapy verification film.

Authors:  Arvind Kumar Shukla; Arun S Oinam; Sanjeev Kumar; I S Sandhu; S C Sharma
Journal:  Rep Pract Oncol Radiother       Date:  2013-05-24

5.  Institutional patient-specific IMRT QA does not predict unacceptable plan delivery.

Authors:  Stephen F Kry; Andrea Molineu; James R Kerns; Austin M Faught; Jessie Y Huang; Kiley B Pulliam; Jackie Tonigan; Paola Alvarez; Francesco Stingo; David S Followill
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-10-21       Impact factor: 7.038

6.  Toward optimizing patient-specific IMRT QA techniques in the accurate detection of dosimetrically acceptable and unacceptable patient plans.

Authors:  Elizabeth M McKenzie; Peter A Balter; Francesco C Stingo; Jimmy Jones; David S Followill; Stephen F Kry
Journal:  Med Phys       Date:  2014-12       Impact factor: 4.071

7.  Intensity Modulated Radiation Therapy Reduces Gastrointestinal Toxicity in Patients Treated with Androgen Deprivation Therapy for Prostate Cancer.

Authors:  Navesh K Sharma; Tianyu Li; David Y Chen; Alan Pollack; Eric M Horwitz; Mark K Buyyounouski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-01       Impact factor: 7.038

8.  Validation of Dolphin dosimetry in three dimensional patient-specific quality assurance programme.

Authors:  Niyas Puzhakkal; Abdullah Kallikuzhiyil Kochunny; Dinesh Makuny; Arun Krishnan M P; Ranjith C Poyil; Vysakh Raveendran
Journal:  Rep Pract Oncol Radiother       Date:  2019-08-12

9.  Trajectory log file sensitivity: A critical analysis using DVH and EPID.

Authors:  Wui Ann Woon; Paul B Ravindran; Piyasiri Ekayanake; Subramani Vikraman; Siti Amirah; Yivonne Y F Lim; Christopher H S Vun; Jamsari Khalid
Journal:  Rep Pract Oncol Radiother       Date:  2018-08-13

10.  Quality Assurance for Small-Field VMAT SRS and Conventional-Field IMRT Using the Exradin W1 Scintillator.

Authors:  Zike Huang; Jian Qiao; Cui Yang; Ming Liu; Jiazhou Wang; Xu Han; Weigang Hu
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.